Julian Harrison
Stock Analyst at BTIG
(1.28)
# 3,519
Out of 4,896 analysts
38
Total ratings
40.62%
Success rate
-11.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Buy | $24 → $25 | $11.45 | +118.34% | 2 | Jun 27, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $4.90 | +716.33% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $13.62 | +208.37% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $14.47 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $26.06 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $2.02 | +345.54% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.59 | +403.14% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $1.38 | +479.71% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $17.12 | +256.41% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $5.25 | +185.99% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $25 | $14.15 | +76.68% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $52.81 | -3.43% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $8.31 | +417.76% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $15.94 | +150.94% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $38.57 | +11.49% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $3.98 | +0.50% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $1.02 | +14,605.88% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $48.88 | -26.35% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $300.16 | - | 2 | Feb 11, 2022 |
Theravance Biopharma
Jun 27, 2025
Maintains: Buy
Price Target: $24 → $25
Current: $11.45
Upside: +118.34%
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $4.90
Upside: +716.33%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $13.62
Upside: +208.37%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.47
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $26.06
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $2.02
Upside: +345.54%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.59
Upside: +403.14%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $1.38
Upside: +479.71%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $17.12
Upside: +256.41%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.25
Upside: +185.99%
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $14.15
Upside: +76.68%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $52.81
Upside: -3.43%
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $8.31
Upside: +417.76%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $15.94
Upside: +150.94%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $38.57
Upside: +11.49%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $3.98
Upside: +0.50%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $1.02
Upside: +14,605.88%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $48.88
Upside: -26.35%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $300.16
Upside: -